The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has presented new clinical data on iadademstat in patients with acute myeloid leukaemia (AML) at the 67th Annual Meeting of the American Society of Hematology (ASH). The results come from two ongoing clinical studies evaluating iadademstat in combination with standard treatments in newly diagnosed AML patients and in relapsed or refractory settings.
In the ALICE-2 study, which investigates the triple combination of iadademstat with azacitidine and venetoclax in newly diagnosed patients who are not candidates for intensive therapy, an overall response rate of 100% and a composite complete remission rate of 90% were observed, with good tolerability. Seventy per cent of enrolled patients were subsequently able to undergo haematopoietic stem cell transplantation, and median overall survival has not yet been reached after nine months of follow-up.
Regarding the FRIDA study, which evaluates iadademstat in combination with gilteritinib in patients with FLT3-mutated relapsed or refractory AML, preliminary data show a composite complete remission rate of 67% at the expansion dose, with a favourable safety profile. These results reinforce the potential of iadademstat as a combination agent in AML subgroups with limited therapeutic options.
According to Oryzon, the data presented at the ASH Congress consolidate the clinical relevance of iadademstat and open up new opportunities to advance its development in haemato-oncology, with the aim of improving clinical outcomes for patients with highly complex leukaemias. In this regard, Dr Carlos Buesa, CEO of Oryzon, stated: “These highly promising preliminary results in first-line AML underscore the potential of iadademstat to deliver meaningful clinical benefit when combined with current standard treatments and to offer patients renewed hope for a truly curative approach.”
Comments